Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker

被引:21
作者
Bragantini, E
Barbi, S
Beghelli, S
Moore, PS
de Manzoni, G
Roviello, F
Tomezzoli, A
Vindigni, C
Baffa, R
Scarpa, A
机构
[1] Univ Verona, Dipartimento Patol, Sez Anat Patol, I-37134 Verona, Italy
[2] Univ Verona, Osped Borgo Trento, Prima Chirurg Clin, I-37100 Verona, Italy
[3] Univ Siena, Policlin Le Scotte, Div Chirurg Oncol, I-53100 Siena, Italy
[4] Osped Borgo Trento, Serv Anat Patol, Verona, Italy
[5] Univ Siena, Dipartimento Patol Umana & Oncol, Sez Anat Patol, Siena, Italy
[6] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Urol, Philadelphia, PA 19107 USA
关键词
stomach; cancer; Fhit; immunohistochemistry; prognosis;
D O I
10.1007/s00432-005-0045-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several studies have reported conflicting results regarding correlations of the loss of Fhit expression with clinicopathological parameters in gastric cancer. We investigated the immunohistochemical expression of Fhit in 362 cases of sporadic advanced gastric adenocarcinoma. The series included 64 cases with microsatellite instability associated with defective mismatch repair genes. Fhit expression resulted absent in 72% of the tumors analyzed. Absence of Fhit expression was more frequent in cases with diffuse and mixed histotype compared to the intestinal histotype (P=0.009). Absence of Fhit expression also correlated with tumor stage (P < 0.001), lymph node involvement (P < 0.001), presence of distant metastasis (P=0.033), and increasing histological grade (P=0.005). Retained Fhit expression also correlated with microsatellite instability as 61% of instable tumors had lost Fhit expression compared to 74% of microsatellite stable cancers (P=0.050). While loss of Fhit correlates with poorer survival in univariate analysis, it is not an independent prognostic factor in multivariate analysis and is thus not of clinical utility.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 31 条
[1]  
[Anonymous], 1992, TNM classification of malignant tumors
[2]  
Baffa R, 1998, CANCER RES, V58, P4708
[3]   Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5'''-P-1,P-3-triphosphate hydrolase [J].
Barnes, LD ;
Garrison, PN ;
Siprashvili, Z ;
Guranowski, A ;
Robinson, AK ;
Ingram, SW ;
Croce, CM ;
Ohta, M ;
Huebner, F .
BIOCHEMISTRY, 1996, 35 (36) :11529-11535
[4]  
Capuzzi D, 2000, CANCER, V88, P24, DOI 10.1002/(SICI)1097-0142(20000101)88:1<24::AID-CNCR5>3.3.CO
[5]  
2-N
[6]  
Chen YJ, 1997, INT J CANCER, V72, P955
[7]   Role of FHIT in human cancer [J].
Croce, CM ;
Sozzi, G ;
Huebner, K .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1618-1624
[8]  
Gemma A, 1997, CANCER RES, V57, P1435
[9]   High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer [J].
Huiping, C ;
Kristjansdottir, S ;
Bergthorsson, JT ;
Jonasson, JG ;
Magnusson, J ;
Egilsson, V ;
Ingvarsson, S .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (05) :728-735
[10]   Regression of upper gastric cancer in mice by FHIT gene delivery [J].
Ishii, H ;
Zanesi, N ;
Vecchione, A ;
Trapasso, F ;
Yendamuri, S ;
Sarti, M ;
Baffa, R ;
During, MJ ;
Huebner, K ;
Fong, LYY ;
Croce, CM .
FASEB JOURNAL, 2003, 17 (10) :1768-+